Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Jonathan Eckard
Kite Pharma's Initial ZUMA Data 'Solid'; Barclays Raises Target To $65
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'
Barclays Morning Research Summary: Commodities, Comcast And Healthcare In Focus
Barclays Initiates 2 Cellular Cancer Therapy Plays With Equal-Weight Rating
Barclays Morning Research Summary: Commodities, Comcast And Healthcare In Focus
Barclays Initiates 2 Cellular Cancer Therapy Plays With Equal-Weight Rating
Mirati Target Lowered From $41 To $27 By Barclays, Overweight Maintained
Here's Why Barclays Is Bullish On Intercept Pharma
Read More...
Jonathan Eckard Recent News
Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside
Why Citigroup Placed An $85 Price Target On Shares Of Alkermes
Citi Analyst Defends Intercept Pharmaceuticals
UPDATE: Citigroup Reiterates on Epizyme Awaiting Further Clarity
UPDATE: Citigroup Upgrades Amarin on Valuation
UPDATE: Citigroup Upgrades Onconova Therapeutics on Favorable Risk-Reward
UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities
UPDATE: Citigroup Downgrades ArQule on Increased Uncertainty Around Lead Cancer Drug Candidate
UPDATE: Citigroup Lowers PT on Vical on Near-Term Challenges
UPDATE: Citigroup Lowers PT on Amarin Following Lighter 2Q13 Sales
Leerink Swann Rates Medivation (MDVN) Market Perform